Over 1,000 Chemotherapy Protocols And Counting

Double-blind, placebo-controlled, phase 3 study Untreated unresectable or metastatic biliary tract cancer Gemcitabine – cisplatin plus Durvalumab (341) or placebo (344)

14 Jun

Skin Cancer (Other than Melanoma)

New Indication: Neoadjuvant Cemiplimab for Cutaneous Squamous Cell Cancer

Phase 2, confirmatory, multicenter, nonrandomized study Resectable stage II, III, or IV (M0) cutaneous squamous-cell carcinoma Cemiplimab 350 mg/21 day (four doses) before surgery

14 Jun

Diffuse Large B Cell Lymphoma

New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL

Open-label, single-center, phase II study Previously untreated non-GCB DLBCL 60 patients Rituximab 375 mg/m2 (D1), lenalidomide 25 mg D(1-10), and ibrutinib 560 mg continuously (RL

14 Jun

Chronic Lymphocytic Leukemia

New Reference: Zanubrutinib in CLL

Open-label, multicentre, phase 3 study Untreated CLL or SLL Patients without del (17) (p13·1)  zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and pa

14 Jun

Melanoma

New Drug: Tebentafusp in Metastatic Uveal Melanoma

Open-label Phase III trial Untreated HLA-A*02:01-positive patients with metastatic uveal melanoma Tebentafusp or the investigator’s choice of therapy with single-agent pembrolizu

7 Jun

Non-Hodgkin LymphomaPrimary Mediastinal Large B-cell Lymphoma

New Reference: Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma

BLOOD, VOL 142, ISSUE 2, P141-145, JUL 2023 Zinzani Pier Luigi et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-1

7 Jun

Breast Cancer

New Indication: Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (MBC)

J Clin Oncol JUL 2023 Kalinsky Kevin et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in

7 Jun

Diffuse Large B Cell LymphomaNon-Hodgkin Lymphoma

New Drug: Glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf Reviewed by Elvin CHALABİYEV, MD on AUG 10, 2023

7 Jun

Cervical Cancer

New Protocol: Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer

J Clin Oncol AUG 31; 2023 Vergote Ignace et al. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries